These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33598570)

  • 1. Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
    Gopie FA; Commiesie E; Baldi S; Kamst M; Kaur D; de Lange WCM; Pinas PS; Stijnberg D; Wongsokarijo M; Zijlmans CWR; de Zwaan R; van Soolingen D; Vreden SGS; de Vries G
    J Clin Tuberc Other Mycobact Dis; 2021 May; 23():100222. PubMed ID: 33598570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study.
    Mboowa G; Namaganda C; Ssengooba W
    BMC Infect Dis; 2014 Sep; 14():481. PubMed ID: 25190040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study.
    Ullah I; Shah AA; Basit A; Ali M; Khan A; Ullah U; Ihtesham M; Mehreen S; Mughal A; Javaid A
    BMC Infect Dis; 2016 Aug; 16():413. PubMed ID: 27519406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century.
    Ngabonziza JCS; Rigouts L; Torrea G; Decroo T; Kamanzi E; Lempens P; Rucogoza A; Habimana YM; Laenen L; Niyigena BE; Uwizeye C; Ushizimpumu B; Mulders W; Ivan E; Tzfadia O; Muvunyi CM; Migambi P; Andre E; Mazarati JB; Affolabi D; Umubyeyi AN; Nsanzimana S; Portaels F; Gasana M; de Jong BC; Meehan CJ
    J Clin Tuberc Other Mycobact Dis; 2022 May; 27():100299. PubMed ID: 35146133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBUS-TBNA in the rapid microbiological diagnosis of drug-resistant mediastinal tuberculous lymphadenopathy.
    Chhajed PN; Vaidya PJ; Mandovra NP; Chavhan VB; Lele TT; Nair R; Leuppi JD; Saha A
    ERJ Open Res; 2019 Oct; 5(4):. PubMed ID: 31754620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistant tuberculosis diagnosis since Xpert
    Lavu EK; Johnson K; Banamu J; Pandey S; Carter R; Coulter C; Aia P; Majumdar SS; Marais BJ; Graham SM; Vince J
    Public Health Action; 2019 Sep; 9(Suppl 1):S12-S18. PubMed ID: 31579644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.
    Wu Z; Rueda ZV; Li T; Zhang Z; Jiang Y; Sha W; Yu F; Chen J; Pan Q; Shen X; Yuan Z
    BMC Infect Dis; 2020 Feb; 20(1):153. PubMed ID: 32070292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Treatment of a Multidrug-Resistant Tuberculosis Patient with a Negative Xpert MTB/RIF Test for Rifampicin-Resistant Tuberculosis in Guizhou Province of China: A Case Report.
    Zhao ZL; Chen L; Zhang H
    Infect Drug Resist; 2020; 13():1351-1355. PubMed ID: 32440172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Performance of Line Probe Assay (Version 2) and Xpert MTB/RIF Assay for Early Diagnosis of Rifampicin-Resistant Pulmonary Tuberculosis.
    Yadav RN; Kumar Singh B; Sharma R; Chaubey J; Sinha S; Jorwal P
    Tuberc Respir Dis (Seoul); 2021 Jul; 84(3):237-244. PubMed ID: 33657709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of the REBA MTB-Rifa® assay for rapid detection of rifampicin resistant Mycobacterium tuberculosis.
    Cho E; Shamputa IC; Kwak HK; Lee J; Lee M; Hwang S; Jeon D; Kim CT; Cho S; Via LE; Barry CE; Lee JS
    BMC Infect Dis; 2013 Oct; 13():478. PubMed ID: 24128118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance.
    Park M; Lalvani A; Satta G; Kon OM
    BMC Infect Dis; 2022 Apr; 22(1):349. PubMed ID: 35392842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thin-Layer-Agar-Based Direct Phenotypic Drug Susceptibility Testing on Sputum in Eswatini Rapidly Detects Mycobacterium tuberculosis Growth and Rifampicin Resistance Otherwise Missed by WHO-Endorsed Diagnostic Tests.
    Ardizzoni E; Ariza E; Mulengwa D; Mpala Q; de La Tour R; Maphalala G; Varaine F; Kerschberger B; Graulus P; Page AL; Niemann S; Dreyer V; Van Deun A; Decroo T; Rigouts L; de Jong BC
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xpert Mycobacterium tuberculosis/Rifampicin-Detected Rifampicin Resistance is a Suboptimal Surrogate for Multidrug-resistant Tuberculosis in Eastern Democratic Republic of the Congo: Diagnostic and Clinical Implications.
    Bisimwa BC; Nachega JB; Warren RM; Theron G; Metcalfe JZ; Shah M; Diacon AH; Sam-Agudu NA; Yotebieng M; Bulabula ANH; Katoto PDMC; Chirambiza JP; Nyota R; Birembano FM; Musafiri EM; Byadunia S; Bahizire E; Kaswa MK; Callens S; Kashongwe ZM
    Clin Infect Dis; 2021 Jul; 73(2):e362-e370. PubMed ID: 32590841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xpert MTB/RIF for rapid detection of rifampicin-resistant Mycobacterium tuberculosis from pulmonary tuberculosis patients in Southwest Ethiopia.
    Tadesse M; Aragaw D; Dimah B; Efa F; Abebe G
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S48-S49. PubMed ID: 28043605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil.
    Feliciano CS; Menon LJB; Anselmo LMP; Dippenaar A; Warren RM; Silva WA; Bollela VR
    ERJ Open Res; 2019 Jul; 5(3):. PubMed ID: 31404338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Xpert MTB/RIF in Decentralized Public Health Settings and Its Effect on Pulmonary TB and DR-TB Case Finding in India.
    Sachdeva KS; Raizada N; Sreenivas A; Van't Hoog AH; van den Hof S; Dewan PK; Thakur R; Gupta RS; Kulsange S; Vadera B; Babre A; Gray C; Parmar M; Ghedia M; Ramachandran R; Alavadi U; Arinaminpathy N; Denkinger C; Boehme C; Paramasivan CN
    PLoS One; 2015; 10(5):e0126065. PubMed ID: 25996389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of
    Xia H; Song Y; Zheng Y; Wang S; Zhao B; He W; Liu D; Ou X; Zhou Y; Zhao Y
    Infect Drug Resist; 2022; 15():1345-1352. PubMed ID: 35378895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sputum culture and drug sensitivity testing outcome among X-pert Mycobacterium tuberculosis/rifampicin-positive, rifampicin-resistant sputum: A retrospective study - Not all rifampicin resistance is multi-drug resistant.
    Kenaope L; Ferreira H; Seedat F; Otwombe K; Martinson NA; Variava E
    J Glob Antimicrob Resist; 2020 Jun; 21():434-438. PubMed ID: 31733411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.